ROLE OF BREAK CLUSTER REGION (BCR) - ABELSON MURINE LEUKIMIA (ABL) EXAMINATION IN CHRONIC MYELOGENOUS LEUKEMIA (CML)

ROLE OF BREAK CLUSTER REGION (BCR) - ABELSON MURINE LEUKIMIA (ABL) EXAMINATION IN CHRONIC MYELOGENOUS LEUKEMIA (CML)

Chronic myelogenous leukemia (CML) is a clonal bone marrow stem cell disorder associated with a characteristic chromosomal translocation called the Philadelphia chromosome which caused a proliferation of mature granulocytes (neutrophils, eosinophils and basophils) and their precursors, increasing un...

Full description

Bibliographic Details
Main Author:	Agung Sosiawan
Format:	Article
Language:	English
Published:	Universitas Airlangga 2015-07-01
Series:	Indonesian Journal of Tropical and Infectious Disease
Online Access:	https://e-journal.unair.ac.id/IJTID/article/view/224

Similar Items

“Preleukemic or smoldering” chronic myelogenous leukemia (CML):BCR-ABL1 positive: A brief case report
by: John M. Bennett, et al.
Published: (2015-01-01)

Critical Requirement of SOS1 for Development of BCR/ABL-Driven Chronic Myelogenous Leukemia
by: Carmela Gómez, et al.
Published: (2022-08-01)

Protocol for isolation and analysis of the leukemia stem cells in BCR-ABL-driven chronic myelogenous leukemia mice
by: Chang Liu, et al.
Published: (2023-03-01)

Detection of bcr-abl Fusion Gene Expression in Chronic Myelogenous
by: Perpustakaan UGM, i-lib
Published: (2004)

Fluorescence in situ hybridization patterns of BCR/ABL1 fusion in chronic myelogenous leukemia at diagnosis
by: Poonam P Jain, et al.
Published: (2012-01-01)

Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis
by: Shuoyi Jiang, et al.
Published: (2021-05-01)

Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches
by: Panagiotis T. Diamantopoulos, et al.
Published: (2021-11-01)

Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
by: Francesca Carofiglio, et al.
Published: (2020-06-01)

Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase?
by: T.P. de Almeida Filho, et al.
Published: (2019-04-01)

Detection of p190BCR-ABL AND p210BCR-ABL fusion transcripts in patients with chronic myeloid leukemia (CML) using qualitative RT-PCR
by: Aya Bonilla, Carlos Alberto, et al.
Published: (2014-10-01)

FISH mapping of Philadelphia negative <it>BCR/ABL1 </it>positive CML
by: Marin David, et al.
Published: (2008-07-01)

Association of Chronic Myelogenous (Basophilic) Leukemia and the BCR/ABL Mutation in a Yucatan Barrow (Sus scrofa domestica)
by: Catherine Takawira, et al.
Published: (2020-11-01)

PENGARUH GIZI TERHADAP RESPON TERAPI PASIEN CHRONIC MYELOCYSTIC LEUKIMIA (CML)
by: Asrini Safitri, et al.
Published: (2018-10-01)

<i>Trifolium Repens</i> Blocks Proliferation in Chronic Myelogenous Leukemia via the BCR-ABL/STAT5 Pathway
by: Federica Sarno, et al.
Published: (2020-02-01)

Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells
by: Seiichi Okabe, et al.
Published: (2023-09-01)

Mutations in the breakpoint cluster region-Abelson murine leukemia 1 gene in Brazilian patients with chronic myeloid leukemia
by: Heloísa Zorzi Costa, et al.
Published: (2018-10-01)

Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms
by: Daniela Zizioli, et al.
Published: (2021-02-01)

Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
by: Shovik Bandyopadhyay, et al.
Published: (2017-01-01)

Digital PCR for BCR-ABL1 Quantification in CML: Current Applications in Clinical Practice
by: Camille C.B. Kockerols, et al.
Published: (2020-12-01)

BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report
by: Benjamin N. Ostendorf, et al.
Published: (2015-08-01)

Quantification of Main Bcr-abl Gene Transcripts in CML Patients Using Competitive RT-PCR
by: Ali Nazemi, et al.
Published: (2016-04-01)

Quantification of main bcr-abl gene transcripts in CML patients using competitive RT-PCR
by: Ali Nazemi, et al.
Published: (2016-04-01)

Concomitant BCR-ABL1 positive chronic myelogenous leukemia emerging in a patient with MPL W515L associated primary myelofibrosis
by: Juan C. Gomez-Gelvez, MD, et al.
Published: (2016-03-01)

Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?
by: Mousa Vatanmakanian, et al.
Published: (2019-04-01)

Fluorescence In situ hybridization signal patterns and intrachromosomal breakpoint cluster region-abelson murine leukemia viral oncogene homolog 1 amplification analysis in imatinib-resistant chronic myelogenous leukemia patients using tricolor dual fusion probe
by: Karthik B K. Bommannan, et al.
Published: (2019-01-01)

Human AQP5 plays a role in the progression of chronic myelogenous leukemia (CML).
by: Young Kwang Chae, et al.
Published: (2008-07-01)

Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
by: Erin Clapper, et al.
Published: (2020-03-01)

Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended.
by: Sarah Huet, et al.
Published: (2014-01-01)

Functionally deregulated AML1/RUNX1 cooperates with BCR-ABL to induce a blastic phase-like phenotype of chronic myelogenous leukemia in mice.
by: Kiyoko Yamamoto, et al.
Published: (2013-01-01)

Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with <i>BCR::ABL1</i> from Chronic Myeloid Leukemia (CML) in Blast Crisis
by: Lara Boucher, et al.
Published: (2023-10-01)

Investigation of the mechanism of USP28-mediated IFITM3 elevation in BCR-ABL-dependent imatinib resistance in CML
by: Zilin Li, et al.
Published: (2024-04-01)

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
by: Maria Stella Pennisi, et al.
Published: (2019-08-01)

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
by: Federica Loscocco, et al.
Published: (2019-09-01)

BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia.
by: Cristina Panuzzo, et al.
Published: (2014-01-01)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
by: Saskia Maletzke, et al.
Published: (2022-01-01)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia.
by: Saskia Maletzke, et al.
Published: (2022-01-01)

BCR-ABL kinase domain mutations in CML patients, experience from a tertiary care center in North India
by: Akhilesh S, et al.
Published: (2024-01-01)

ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance.
by: Zhiqiang Wang, et al.
Published: (2014-06-01)

Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)
by: Ladislav Chrobák, et al.
Published: (2003-01-01)

Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemia.
by: Dawne N Shelton, et al.
Published: (2022-01-01)